Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Processed by the Body in Healthy Volunteers After Single-dose Administration, and in Non-segmental Vitiligo Patients and Alopecia Areata Patients After Multiple-dose Administration

NCT07554222 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy
Active Non-segmental Vitiligo
Severe Alopecia Areata

Interventions

DRUG: placebo
DRUG: Baricitinib tablets
DRUG: IBI3013

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.